AstraZeneca’s rare disease unit Alexion has penned a $825 million deal for adeno-associated virus (AAV) capsids from existing ...

JCR Pharmaceuticals has signed a licence agreement with Alexion, AstraZeneca Rare Disease, for its proprietary JUST-AAV ...

JCR announced that it has entered into a license agreement with Alexion, for JCR’s new, proprietary JUST-AAV capsids to ...

The deal gives AstraZeneca’s rare disease unit Alexion access to specialized capsids developed by the Japanese biotech JCR ...

The company in question is New Haven, Conn.-based Alexion Pharmaceuticals -- best-known for Soliris, a drug that costs insurance companies about $440,000 a year per patient. The reason for the ...

A $440,000-a-year treatment for rare diseases turned Alexion Pharmaceuticals into biotech's biggest entrepreneurial success story and the health care system's biggest paradox. It also landed them ...

Alexion said it will pay $115 in cash and a portion of its stock for each Synageva share. That puts the total per-share price at about $226, based on the Tuesday closing price of Alexion shares.

Britain's AstraZeneca (AZN.L) has agreed to buy U.S. drugmaker Alexion Pharmaceuticals (ALXN.O) for $39 billion in its largest ever deal, diversifying away from its fast-growing cancer business in ...

The huge premium drug maker Alexion Pharmaceuticals is paying for Synageva BioPharma—$8.4 billion, or more than double Synageva’s market value—shows how hot the market has become for rare ...

Last fall, Alexion Pharmaceuticals spent more than $900 million to acquire a company with a drug in development for a rare kidney disease. On Thursday, it dropped the program. The Boston-based ...

Alexion Pharmaceuticals agreed to pay more than $21 million to settle claims it bribed government officials to increase prescription drug sales in Turkey and Russia, the U.S. Securities and ...